Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group

J. P. Neijt; M. E L van der Burg; J. P. Guastalla; M. George; M. Piccart; J. Vermorken; F. Carnino; N. Rotmensz

doi:10.3109/02841868909092290

Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group

J. P. Neijt, M. E L van der Burg, J. P. Guastalla, M. George, M. Piccart, J. Vermorken, F. Carnino, N. Rotmensz

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m² as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.

Original language	English
Pages (from-to)	663-665
Number of pages	3
Journal	Acta Oncologica
Volume	28
Issue number	5
DOIs	https://doi.org/10.3109/02841868909092290
Publication status	Published - 1989

Keywords

Advanced ovarian cancer
Mitozolomide
Phase II study

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Hematology

Access to Document

10.3109/02841868909092290

Cite this

Phase ii trial of mitozolomide in patients with advanced ovarian cancer : A study of the eortc gynecological cancer cooperative group. / Neijt, J. P.; van der Burg, M. E L; Guastalla, J. P.; George, M.; Piccart, M.; Vermorken, J.; Carnino, F.; Rotmensz, N.

In: Acta Oncologica, Vol. 28, No. 5, 1989, p. 663-665.

Research output: Contribution to journal › Article › peer-review

@article{453518baac874d40b3bdce51ddcfc6bf,

title = "Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group",

abstract = "Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.",

keywords = "Advanced ovarian cancer, Mitozolomide, Phase II study",

author = "Neijt, {J. P.} and {van der Burg}, {M. E L} and Guastalla, {J. P.} and M. George and M. Piccart and J. Vermorken and F. Carnino and N. Rotmensz",

year = "1989",

doi = "10.3109/02841868909092290",

language = "English",

volume = "28",

pages = "663--665",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Phase ii trial of mitozolomide in patients with advanced ovarian cancer

T2 - A study of the eortc gynecological cancer cooperative group

AU - Neijt, J. P.

AU - van der Burg, M. E L

AU - Guastalla, J. P.

AU - George, M.

AU - Piccart, M.

AU - Vermorken, J.

AU - Carnino, F.

AU - Rotmensz, N.

PY - 1989

Y1 - 1989

N2 - Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.

AB - Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.

KW - Advanced ovarian cancer

KW - Mitozolomide

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=0024842140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024842140&partnerID=8YFLogxK

U2 - 10.3109/02841868909092290

DO - 10.3109/02841868909092290

M3 - Article

C2 - 2590542

AN - SCOPUS:0024842140

VL - 28

SP - 663

EP - 665

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 5

ER -

Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this